Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents, but some exhibit resistance mechanisms
linked to anti-apoptotic Bcl-2 functions, such as BH3-only protein silencing. HDAC inhibitors that reactivate BH3-only family
members might offer an improved therapeutic approach. We show here that a novel seleno-α-keto acid triggers global histone...
Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents, but some exhibit resistance mechanisms
linked to anti-apoptotic Bcl-2 functions, such as BH3-only protein silencing. HDAC inhibitors that reactivate BH3-only family
members might offer an improved therapeutic approach. We show here that a novel seleno-α-keto acid triggers global histone...
Full Text:
., Rajendran, P., Kim, E., Dashwood, W. M., Pinto, J. T., ... &
Dashwood, R. H. (2014). HDAC8 and STAT3
Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents, but some exhibit resistance mechanisms
linked to anti-apoptotic Bcl-2 functions, such as BH3-only protein silencing. HDAC inhibitors that reactivate BH3-only family
members might offer an improved therapeutic approach. We show here that a novel seleno-α-keto acid triggers global histone...